Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

Cited by (7,499)

Items 1,101–1,200 of 7,499

1. Renal protection by sodium-glucose cotransporter 2 inhibitors and its underlying mechanisms in diabetic kidney disease
   Akira Mima · 2018 · Journal of Diabetes and its Complications
2. Treatment approach to type 2 diabetes: Past, present and future
   Kristina Blaslov, Fran Stjepan Naranđa, Ivan Kruljac, Ivana Pavlić Renar · 2018 · World Journal of Diabetes
3. A Narrative Review of Diabetic Kidney Disease: Previous and Current Evidence-Based Therapeutic Approaches
   Akira Mima · 2022 · Advances in Therapy
4. The Study on COgnition and Prognosis in the Elderly (SCOPE) – Major CV events and stroke in subgroups of patients
   Peter Trenkwalder, Dag Elmfeldt, Albert Hofman D, Hans Lithell, Bertil Olofsson, Vasilios Papademetriou, Ingmar Gr. Skoog, Alberto Zanchetti · 2005 · Blood Pressure
5. Angiotensin receptor blockers: Therapeutic targets and cardiovascular protection
   Luis Miguel Ruilope, Enrico Agabiti Rosei, George L. Bakris, Giuseppe Mancia, Neil R Poulter, Stefano Taddei, Thomas Unger, Massimo Volpe, Bernard Waeber, Faiez M. Zannad · 2005 · Blood Pressure
6. Antihypertensive medication and their impact on cancer incidence: a mixed treatment comparison meta-analysis of randomized controlled trials
   Craig Ian Coleman, William L. Baker, Jeffrey Kluger, C Michael White · 2008 · Journal of Hypertension
7. Effects of Renin-Angiotensin System Blockers on Renal Outcomes and All-cause Mortality in Patients With Diabetic Nephropathy: An Updated Meta-analysis
   Pantelis A. Sarafidis, Panagiotis C. Stafylas, Angeliki Kanaki, Anastasios N. Lasaridis · 2008 · American Journal of Hypertension
8. Diabetes and Cardiovascular Diseases
   Jasjeet Kaur, Parminder Singh, James R. Sowers · 2002 · American Journal of Therapeutics
9. Reduced risk of heart failure with intensified multifactorial intervention in individuals with type 2 diabetes and microalbuminuria: 21 years of follow-up in the randomised Steno-2 study
   Oellgaard, Jens, Gæde, Peter, Rossing, Peter, Rørth, Rasmus, Køber, Lars, Parving, Hans-Henrik, Pedersen, Oluf · 2018 · Diabetologia
10. Adherence to the Kidney Disease: Improving Global Outcomes CKD Guideline in Nephrology Practice Across Countries
    Bénédicte Stengel, Daniel G. Muenz, Charlotte Tu, Élodie Speyer, Natália Alencar de Pinho, Christian Combe, Kunihiro Yamagata, Helmut Reichel, Danilo Fliser, Ziad A. Massy et al. · 2020 · Kidney International Reports
11. The Growing Challenge of Chronic Kidney Disease: An Overview of Current Knowledge
    Rikke Borg, Nicholas Carlson, Jens Søndergaard, Frederik Persson · 2023 · International Journal of Nephrology
12. Prevention of the complications of diabetes.
    Aaron I. Vinik, Etta Johanna Vinik · 2003 · PubMed
13. Efficacy and Safety of Tangshen Formula on Patients with Type 2 Diabetic Kidney Disease: A Multicenter Double-Blinded Randomized Placebo-Controlled Trial
    Ping Li, Yiping Chen, Jianping Liu, Jing Hong, Yueyi Deng, Fang Yang, Jin Xiu-ping, Jing Sheng Gao, Jing Li, Hui Fang et al. · 2015 · PLoS ONE
14. Who Should Be Targeted for CKD Screening? Impact of Diabetes, Hypertension, and Cardiovascular Disease
    Allan J. Collins, Joseph A. Vassalotti, Changchun Wang, Suying Li, David T. Gilbertson, Jiannong Liu, Robert N. Foley, Shu‐Cheng Chen, Thomas J. Arneson · 2009 · American Journal of Kidney Diseases
15. Treatment of metabolic syndrome
    Arati Wagh, Neil J. Stone · 2004 · Expert Review of Cardiovascular Therapy
16. Vitamin D Deficiency, Inflammation, and Albuminuria in Chronic Kidney Disease: Complex Interactions
    Tamara Isakova, Orlando M. Gutiérrez, Neha M. Patel, Dennis L. Andress, Myles Selig Wolf, Adeera Levin · 2010 · Journal of Renal Nutrition
17. Underuse of ACE Inhibitors and Angiotensin II Receptor Blockers in Elderly Patients With Diabetes
    Wolfgang C. Winkelmayer­, Michael A. Fischer, Sebastian Schneeweiß, Philip S. Wang, Raisa Levin, Jerry Avorn · 2005 · American Journal of Kidney Diseases
18. Renoprotection with SGLT2 inhibitors in type 2 diabetes over a spectrum of cardiovascular and renal risk
    Francesco Giorgino, Jiten P Vora, Peter Fenici, Anna Solini · 2020 · Cardiovascular Diabetology
19. Kidney Disease in Diabetic Patients: From Pathophysiology to Pharmacological Aspects with a Focus on Therapeutic Inertia
    Guido Gembillo, Ylenia Ingrasciotta, Salvatore Crisafulli, Nicoletta Luxi, Rossella Siligato, Domenico Santoro, Gianluca Trifirò · 2021 · International Journal of Molecular Sciences
20. Diabetic nephropathy: a disorder of oxygen metabolism?
    Toshio Miyata, Charles van Ypersele de Strihou · 2009 · Nature Reviews Nephrology
21. Effect of Blood Pressure on Early Decline in Kidney Function Among Hypertensive Men
    Suma X. Vupputuri, Vecihi Batuman, Paul Muntner, Lydia Bazzano, John J. Lefante, Paul Kieran Whelton, Jiang He · 2003 · Hypertension
22. 2010 Guidelines of the Taiwan Society of Cardiology for the Management of Hypertension
    Chern‐En Chiang, Tzung‐Dau Wang, Yi-Heng Li, Tsung‐Hsien Lin, Kuo‐Liong Chien, Hung‐I Yeh, Kou‐Gi Shyu, Wei-Chuen Tsai, Ting-Hsing Chao, Juey‐Jen Hwang et al. · 2010 · Journal of the Formosan Medical Association
23. Kidney Function During and After Withdrawal of Long-Term Irbesartan Treatment in Patients With Type 2 Diabetes and Microalbuminuria
    Steen Andersen, Jens Brøchner‐Mortensen, Hans‐Henrik Parving, Irbesartan in Patients With Type 2 Diabetes and Microalbuminuria Study Group · 2003 · Diabetes Care
24. A health economic analysis of screening and optimal treatment of nephropathy in patients with type 2 diabetes and hypertension in the USA
    Andrew John Palmer, W. J. Valentine, R. Chen, Nazanin Mehin, Sylvie Gabriel, B. Bregman, Roger A. Rodby · 2007 · Nephrology Dialysis Transplantation
25. A Role for Angiotensin II Type 1 Receptors on Bone Marrow-Derived Cells in the Pathogenesis of Angiotensin II–Dependent Hypertension
    Steven D. Crowley, Young-Soo Song, Gregory M. Sprung, Robert Griffiths, Matthew A. Sparks, Ming Yan, James L. Burchette, David N. Howell, Eugene E. Lin, Benson Okeiyi et al. · 2009 · Hypertension
26. The Role of Autophagy in the Pathogenesis of Diabetic Nephropathy
    Kosuke Yamahara, Mako Yasuda, Shinji Kume, Daisuke Koya, Hiroshi Maegawa, Takashi Uzu · 2013 · Journal of Diabetes Research
27. Molecular targets for treatment of kidney fibrosis
    Peter Y. Chuang, Madhav C. Menon, Cijiang He · 2012 · Journal of Molecular Medicine
28. Pilot study of losartan for pulmonary hypertension in chronic obstructive pulmonary disease
    Nicholas W. Morrell, Matthew A Higham, Peter Phillips, Haleema Shakur‐Still, Paul J. Robinson, Ray J Beddoes · 2005 · Respiratory Research
29. Anti-inflammatory effects of short-term pioglitazone therapy in men with advanced diabetic nephropathy
    Rajiv Agarwal · 2005 · American Journal of Physiology-Renal Physiology
30. Chronic kidney disease: issues and establishing programs and clinics for improved patient outcomes
    Wendy L. St. Peter, Anton C. Schoolwerth, Tracy McGowan, William M. McClellan · 2003 · American Journal of Kidney Diseases
31. Progression of renal insufficiency in type 2 diabetes with and without microalbuminuria: results of the Heart Outcomes and Prevention Evaluation (HOPE) randomized study
    Johannes F.E. Mann, Hertzel C. Gerstein, Qilong Yi, Jörg Franke, Eva Lonn, Byron J. Hoogwerf, Andrew M. Rashkow, Salim Yusuf · 2003 · American Journal of Kidney Diseases
32. Insights into the mechanisms of renal fibrosis: is it possible to achieve regression?
    Christos Chatziantoniou, Jean‐Claude Dussaule · 2005 · American Journal of Physiology-Renal Physiology
33. Genetic Variation in the Renin-Angiotensin System and Progression of Diabetic Nephropathy
    Peter Karl Jacobsen, Lise Tarnow, Bendix Carstensen, Peter Hambak Hovind, Odette Poirier, Hans‐Henrik Parving · 2003 · Journal of the American Society of Nephrology
34. A novel potential therapy for diabetic nephropathy and vascular complications: protein kinase C β inhibition
    Katherine R. Tuttle, Pamela W. Anderson · 2003 · American Journal of Kidney Diseases
35. State of the art paper Heart failure in the diabetic population – pathophysiology, diagnosis and management
    Jacek Kasznicki, Józef Drzewoski · 2014 · Archives of Medical Science
36. First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension
    Yu Jie Chen, Liang Jin Li, Wen Lu Tang, Jia Yang Song, Ru Qiu, Qian Li, Hao Xue, James M Wright · 2018 · Cochrane Database of Systematic Reviews
37. Edema formation in congestive heart failure and the underlying mechanisms
    Zaid A. Abassi, Emad E. Khoury, Tony Karram, Doron Aronson · 2022 · Frontiers in Cardiovascular Medicine
38. Mechanisms of diabetic kidney disease and established and emerging treatments
    Victor Martinez Leon, Rachel Hilburg, Katalin Suszták · 2025 · Nature Reviews Endocrinology
39. Urinary proteome analysis enables assessment of renoprotective treatment in type 2 diabetic patients with microalbuminuria
    Sten Andersen, Harald Mischak, Petra Zürbig, Hans‐Henrik Parving, Peter R Rossing · 2010 · BMC Nephrology
40. Intracardiac and Intrarenal Renin-Angiotensin Systems: Mechanisms of Cardiovascular and Renal Effects
    Veena Raizada, BETTY J. SKIPPER, Wentao Luo, Jeffrey K. Griffith · 2007 · Journal of Investigative Medicine
41. Experimental mild renal insufficiency mediates early cardiac apoptosis, fibrosis, and diastolic dysfunction: a kidney-heart connection
    Fernando L. Martín, Paul M. McKie, Alessandro Cataliotti, S. Jeson Sangaralingham, Josef K. Korinek, Brenda K. Huntley, Elise A. Oehler, Gerald E. Harders, Tomoko Ichiki, Sarah Mangiafico et al. · 2011 · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology
42. 2003 European Society of Hypertension-European Society of Cardiology Guidelines for the Management of Arterial Hypertension
    Sverre Erik Kjeldsen · 2004 · Heart Drug
43. Should Angiotensin II Receptor Blockers and Statins Be Combined?
    Georg Nickenig · 2004 · Circulation
44. Randomized controlled crossover study of the effect on proteinuria and blood pressure of adding an angiotensin II receptor antagonist to an angiotensin converting enzyme inhibitor in normotensive patients with chronic renal disease and proteinuria
    Priscilla Kincaid‐Smith, Kenneth F. Fairley, David Packham · 2002 · Nephrology Dialysis Transplantation
45. Conventional and genetic evidence on the association between adiposity and CKD
    Zhu, Pengfei, Herrington, William G., Haynes, Richard, Emberson, Jonathan, Landray, Martin J., Sudlow, Cathie L.M., Woodward, Mark, Baigent, Colin, Lewington, Sarah, Staplin, Natalie · 2021 · Journal of the American Society of Nephrology
46. A randomized trial of low-protein diet in type 1 and in type 2 diabetes mellitus patients with incipient and overt nephropathy
    Dussol, Bertrand, Iovanna, Cecilia, Raccah, Denis, Darmon, Patrice, Morange, Sophie, Vague, Philippe, Vialettes, Bernard, Oliver, Charles, Loundoun, Anderson, Berland, Yvon · 2005 · Journal of Renal Nutrition
47. Fatty acid transport protein-2 regulates glycemic control and diabetic kidney disease progression
    Shenaz Khan, Robert J. Gaivin, Caroline M. Abramovich, M O Boylan, Jorge Calles, Jeffrey R. Schelling · 2020 · JCI Insight
48. Abnormal lactate metabolism is linked to albuminuria and kidney injury in diabetic nephropathy
    Kengo Azushima, Jean‐Paul Kovalik, Takahiro Yamaji, Jianhong Ching, Tze Wei Chng, Jing Guo, Jianjun Liu, Mien T.X. Nguyen, Rashidah Binte Sakban, Simi Elizabeth George et al. · 2023 · Kidney International
49. The prevention of cardiovascular disease in cancer survivors.
    Iyad N. Daher, Tina R Daigle, Nirmanmoh Bhatia, Jean‐Bernard Durand · 2012 · Europe PMC (PubMed Central)
50. Renin^|^ndash;Angiotensin System, Hypertension, and Chronic Kidney Disease: Pharmacogenetic Implications
    Paulo Caleb Júnior Lima Santos, José Eduardo Krieger, Alexandre C. Pereira · 2012 · Journal of Pharmacological Sciences
51. Proteome Analysis of Serum from Type 2 Diabetics with Nephropathy
    Hyun-Jung Kim, Eun-Hee Cho, Ji-Hye Yoo, Pan-Kyeom Kim, Jun‐Seop Shin, Mi-Ryung Kim, Chan‐Wha Kim · 2007 · Journal of Proteome Research
52. Amygdalin inhibits renal fibrosis in chronic kidney disease
    Junqi Guo, Weizheng Wu, Mingxiong Sheng · 2013 · Molecular Medicine Reports
53. The pathobiology of diabetic vascular complications—cardiovascular and kidney disease
    Stephen P. Gray, Karin Agnes Maria Jandeleit-Dahm · 2014 · Journal of Molecular Medicine
54. Prevalence of albuminuria in Australia: The AusDiab Kidney Study
    Robert C. Atkins, Kevan Roy Polkinghorne, Esther M. Briganti, Jonathan E. Shaw, Paul Zimmet, Steven James Chadban · 2004 · Kidney International
55. Albuminuria: A Target for Treatment of Type 2 Diabetic Nephropathy
    Dick de Zeeuw · 2007 · Seminars in Nephrology
56. Hypertensive nephropathy: prevention and treatment recommendations
    Peter D Hart, George L. Bakris · 2010 · Expert Opinion on Pharmacotherapy
57. Prevalence and socio-economic aspects of chronic kidney disease
    J. Bommer · 2002 · Nephrology Dialysis Transplantation
58. Blood pressure reduction and renin-angiotensin system inhibition for prevention of congestive heart failure: a meta-analysis
    Paolo Verdecchia, Fabio Angeli, C. Cavallini, Roberto Gattobigio, Giorgio Gentile, Jan A. Staessen, Gianpaolo Reboldi · 2008 · European Heart Journal
59. The contributions of risk factor trends to cardiometabolic mortality decline in 26 industrialized countries
    Mariachiara Di Cesare, James E. Bennett, Nicola G. Best, George Stevens, Goodarz Danaei, Majid Ezzati · 2013 · International Journal of Epidemiology
60. Diabetes Management Issues for Patients With Chronic Kidney Disease
    Kerri L. Cavanaugh · 2007 · Clinical Diabetes
61. Betanin, isolated from fruits of Opuntia elatior Mill attenuates renal fibrosis in diabetic rats through regulating oxidative stress and TGF-β pathway
    Brijesh Sutariya, Madhusudan N. Saraf · 2017 · Journal of Ethnopharmacology
62. Albuminuria, Proteinuria, and Renal Disease Progression in Children with CKD
    Dana Y. Fuhrman, Michael F. Schneider, Katherine M. Dell · 2017 · Clinical Journal of the American Society of Nephrology
63. ACE inhibitors and ARBs: Managing potassium and renal function
    Tasnim Momoniat, Duha Ilyas, Sunil Bhandari · 2019 · Cleveland Clinic Journal of Medicine
64. Gut Microbial Changes in Diabetic db/db Mice and Recovery of Microbial Diversity upon Pirfenidone Treatment
    Harinder Singh, Satoshi Miyamoto, Manjula Darshi, Manolito Torralba, Keehwan Kwon, Kumar Sharma, Rembert Pieper · 2020 · Microorganisms
65. Therapeutic Insights in Chronic Kidney Disease Progression
    Amir Shabaka, Clara Cases‐Corona, Gema Maria Fernandez Juarez · 2021 · Frontiers in Medicine
66. Combination Therapy with Paricalcitol and Enalapril Ameliorates Cardiac Oxidative Injury in Uremic Rats
    Kazim M. Husain, León Ferder, Masahide Mizobuchi · 2008 · American Journal of Nephrology
67. CONSENSUS to EMPHASIS: The Overwhelming Evidence which Makes Blockade of the Renin–Angiotensin–Aldosterone System the Cornerstone of Therapy for Systolic Heart Failure
    John J.V. McMurray · 2011 · European Journal of Heart Failure
68. Dynamic (re)organization of the podocyte actin cytoskeleton in the nephrotic syndrome
    Jun Seok Oh, Jochen Reiser, Peter H. Mundel · 2004 · Pediatric Nephrology
69. Long-term effect of modification of dietary protein intake on the progression of diabetic nephropathy: a randomised controlled trial
    on behalf of the Low-Protein Diet Study Group, Daisuke Koya, Masakazu Haneda, S. Inomata, Yu Suzuki, Daisuke Suzuki, Hirofumi Makino, Kenichi Shikata, Yoko Murakami, Yasuhiko Tomino et al. · 2009 · Diabetologia
70. Effect of Dual Blockade of the Renin-Angiotensin System on the Progression of Type 2 Diabetic Nephropathy: A Randomized Trial
    Gema Maria Fernandez Juarez, José Luño, Vicente Barrio, Soledad García de Vinuesa, Manuel Praga, Marián Goicoechea, Victoria Cachofeiro, Javier Nieto, Francisco Fernández Vega, A Tato et al. · 2012 · American Journal of Kidney Diseases
71. Angiotensin type 2 receptor actions contribute to angiotensin type 1 receptor blocker effects on kidney fibrosis
    Takashi Naito, Lijun Ma, Haichun Yang, Yiqin Zuo, Yi‐Wei Tang, Jee‐Young Han, Valentina Kon, Agnes B. Fogo · 2009 · American Journal of Physiology-Renal Physiology
72. Irbesartan Treatment Reduces Biomarkers of Inflammatory Activity in Patients With Type 2 Diabetes and Microalbuminuria
    Frederik Persson, Peter R Rossing, Peter Hambak Hovind, Coen D.A. Stehouwer, Casper G. Schalkwijk, Lise Tarnow, Hans‐Henrik Parving · 2006 · Diabetes
73. The renin–angiotensin system and the long‐term complications of diabetes: pathophysiological and therapeutic considerations
    Richard E. Gilbert, Henry Krum, Jennifer L. Wilkinson‐Berka, Darren J. Kelly · 2003 · Diabetic Medicine
74. N-Acetyl-Seryl-Aspartyl-Lysyl-Proline Inhibits TGF-β–Mediated Plasminogen Activator Inhibitor-1 Expression via Inhibition of Smad Pathway in Human Mesangial Cells
    Keizo Kanasaki, Daisuke Koya, Toshiro Sugimoto · 2003 · Journal of the American Society of Nephrology
75. International Society of Hypertension (ISH): statement on blood pressure lowering and stroke prevention.
    John Philip Chalmers, Angela L. Todd, Neil Chapman, Lawrie Beilin, Stephen M. Davis, Geoffrey Alan Donnan, Michael S. Frommer, Rachel Huxley, Claude J. M. Lenfant, Stephen W MacMahon et al. · 2003 · PubMed
76. Diabetic kidney disease: New clinical and therapeutic issues. Joint position statement of the Italian Diabetes Society and the Italian Society of Nephrology on “The natural history of diabetic kidney disease and treatment of hyperglycemia in patients with type 2 diabetes and impaired renal function”
    Pugliese, Giuseppe, Penno, Giuseppe, Natali, Andrea, Barutta, Federica, Di Paolo, Salvatore, Reboldi, Gianpaolo, Gesualdo, Loreto, De Nicola, Luca · 2019 · Nutrition, Metabolism and Cardiovascular Diseases
77. Sodium Glucose Cotransporter-2 Inhibition and Cardiorenal Protection
    David Z.I. Cherney, Ayodele Odutayo, Ronnie Aronson, Justin Adrian Ezekowitz, John D. Parker · 2019 · Journal of the American College of Cardiology
78. A Systematic Review of the Economic Burden of Type 2 Diabetes in Malaysia
    Kurubaran Ganasegeran, Chee Peng Hor, Mohd Fadzly Amar Jamil, Hong Chuan Loh, Juliana Mohd Noor, Norshahida Abdul Hamid, Purnima Devi Suppiah, Mohd Rizal Abdul Manaf, Alan Swee Hock Ch’ng, Irene Looi · 2020 · International Journal of Environmental Research and Public Health
79. Management of hypertension and renin-angiotensin-aldosterone system blockade in adults with diabetic kidney disease: Association of British Clinical Diabetologists and the Renal Association UK guideline update 2021
    Debasish Banerjee, Peter H. Winocour, Tahseen Ahmad Chowdhury, Prasenjit De, Mona M. Wahba, Rosa Montero, Damian G. Fogarty, Andrew Frankel, Janaka J. Karalliedde, Patrick Barry Mark et al. · 2022 · BMC Nephrology
80. Delayed referral to a nephrologist: outcomes among patients who survive at least one year on dialysis
    Alan Cass, Joan Cunningham, Zhiqiang Wang, Wendy E. Hoy, Peter C Arnold, Paul L. Snelling · 2002 · The Medical Journal of Australia
81. Inhibition of RAS in diabetic nephropathy
    Kirk Nicholas Campbell, Rabi Yacoub · 2015 · International Journal of Nephrology and Renovascular Disease
82. Plasma aldosterone concentration in the patient with diabetes mellitus Rapid Communication
    Norman K. Hollenberg, Radomir D Stevanovic, Anupam Agarwal, Maria Cecilia Lansang, Deborah A. Price, Lori M. Laffel, Gordon H. Williams, Naomi D.L. Fisher · 2004 · Kidney International
83. Public Health Consequences of Chronic Kidney Disease
    Daniel E. Weiner · 2009 · Clinical Pharmacology & Therapeutics
84. Pitavastatin, an HMG-CoA Reductase Inhibitor, Exerts eNOS-Independent Protective Actions Against Angiotensin II–Induced Cardiovascular Remodeling and Renal Insufficiency
    Shusuke Yagi, Ken‐ichi Aihara, Yasumasa Ikeda, Yuka Sumitomo, Sumiko Yoshida, Takayuki Ise, Takashi Iwase, Kazue Ishikawa, Hiroyuki Azuma, Masashi Akaike et al. · 2007 · Circulation Research
85. Prevention of Hypertension and Its Complications
    John M. Flack, Rosalind M. Peters, Tariq Shafi, Hisham Alrefai, Samar A. Nasser, Errol D. Crook · 2003 · Journal of the American Society of Nephrology
86. Improved Survival and Renal Prognosis of Patients With Type 2 Diabetes and Nephropathy With Improved Control of Risk Factors
    Guðbjörg Andrésdóttir, M. L. Jensen, Bendix Carstensen, Hans‐Henrik Parving, Kasper Rossing, Tine W. Hansen, Peter R Rossing · 2014 · Diabetes Care
87. ACE Inhibition Versus Angiotensin Type 1 Receptor Antagonism
    Nancy Jeanne Brown, Sandeep Kumar, Corrie Painter, Douglas E. Vaughan · 2002 · Hypertension
88. Metabolic and hemodynamic effects of sodium‐dependent glucose cotransporter 2 inhibitors on cardio‐renal protection in the treatment of patients with type 2 diabetes mellitus
    Atsunori Kashiwagi, Hiroshi Maegawa · 2017 · Journal of Diabetes Investigation
89. Advances in the management of chronic kidney disease
    Teresa K. Chen, Melanie P. Hoenig, Dorothea Nitsch, Morgan Erika Grams · 2023 · BMJ
90. Lowering blood pressure for cardiovascular risk reduction
    Gordon T. McInnes · 2005 · Journal of Hypertension
91. Reducing pill burden and helping with medication awareness to improve adherence
    Barbara J. Farrell, Véronique French-Merkley, Nafisa Ingar · 2013 · Canadian Pharmacists Journal / Revue des Pharmaciens du Canada
92. Efficacy and safety of initial combination therapy with amlodipine/valsartan compared with amlodipine monotherapy in black patients with stage 2 hypertension: the EX-STAND study
    John M. Flack, David A. Calhoun, Lisa C. Satlin, Michaela Carla Barbier, Robert J. Hilkert, Patrick Brunel · 2009 · Journal of Human Hypertension
93. Urine haptoglobin levels predict early renal functional decline in patients with type 2 diabetes
    Nishant M. Bhensdadia, Kelly J. Hunt, Maria Fernanda Lopes-Virella, Jody M. Tucker, Mohammad R. Mataria, Joseph L. Alge, Benjamin A. Neely, Michael G. Janech, John M. Arthur · 2013 · Kidney International
94. Diabetes & coronary heart disease: Current perspectives
    Mohammed Kumail Ali, K.M. Venkat Narayan, Nikhil Tandon · 2010 · The Indian Journal of Medical Research
95. Renin Angiotensin Aldosterone System Blockade and Renal Disease in Patients With Type 2 Diabetes
    Juliana C.N. Chan, Nelson M. S. Wat, Wing‐Yee So, Karen S.L. Lam, Chin-Teong Chua, Kok-Seng Wong, Zaki Morad, Tania Z. Dickson, Darcy A. Hille, Zhongxin Zhang et al. · 2004 · Diabetes Care
96. Effects of blood pressure lowering treatment in hypertension
    Costas Thomopoulos, Gianfranco Parati, Alberto Zanchetti · 2016 · Journal of Hypertension
97. Effects of verapamil added-on trandolapril therapy in hypertensive type 2 diabetes patients with microalbuminuria: the BENEDICT-B randomized trial
    Piero Luigi Ruggenenti, Anna Fassi, Aneliya Ilieva Parvanova, Ilian Petrov Iliev, Carlos R. Chiurchiu, Nadia Rubis, Giulia Gherardi, Bogdan Ene‐Iordache, Flavio Gaspari, Annalisa Perna et al. · 2010 · Journal of Hypertension
98. Angiotensin II type 1 receptor polymorphisms and susceptibility to hypertension: A HuGE review
    Amy K. Mottl, David A. Shoham, Kari E. North · 2008 · Genetics in Medicine
99. Exenatide Reduces Urinary Transforming Growth Factor-β1 and Type IV Collagen Excretion in Patients with Type 2 Diabetes and Microalbuminuria
    Hong Zhang, Xiangcheng Zhang, Changjun Hu, Weiping Lu · 2012 · Kidney & Blood Pressure Research
100. Effect of Pentoxifylline on GFR Decline in CKD: A Pilot, Double-Blind, Randomized, Placebo-Controlled Trial
     Robert M. Perkins, Matthew C. Aboudara, Alice L. Uy · 2009 · American Journal of Kidney Diseases